These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 22038996)
1. Targeted therapy for BRAFV600E malignant astrocytoma. Nicolaides TP; Li H; Solomon DA; Hariono S; Hashizume R; Barkovich K; Baker SJ; Paugh BS; Jones C; Forshew T; Hindley GF; Hodgson JG; Kim JS; Rowitch DH; Weiss WA; Waldman TA; James CD Clin Cancer Res; 2011 Dec; 17(24):7595-604. PubMed ID: 22038996 [TBL] [Abstract][Full Text] [Related]
2. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Huillard E; Hashizume R; Phillips JJ; Griveau A; Ihrie RA; Aoki Y; Nicolaides T; Perry A; Waldman T; McMahon M; Weiss WA; Petritsch C; James CD; Rowitch DH Proc Natl Acad Sci U S A; 2012 May; 109(22):8710-5. PubMed ID: 22586120 [TBL] [Abstract][Full Text] [Related]
3. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Dasgupta T; Olow AK; Yang X; Hashizume R; Nicolaides TP; Tom M; Aoki Y; Berger MS; Weiss WA; Stalpers LJ; Prados M; James CD; Mueller S; Haas-Kogan DA J Neurooncol; 2016 Feb; 126(3):385-93. PubMed ID: 26384810 [TBL] [Abstract][Full Text] [Related]
4. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495 [TBL] [Abstract][Full Text] [Related]
6. Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells. Ahn JH; Lee YW; Ahn SK; Lee M Life Sci; 2014 May; 104(1-2):38-46. PubMed ID: 24721513 [TBL] [Abstract][Full Text] [Related]
7. A Combinatorial Strategy for Targeting Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621 [TBL] [Abstract][Full Text] [Related]
8. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720 [TBL] [Abstract][Full Text] [Related]
9. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Sievert AJ; Lang SS; Boucher KL; Madsen PJ; Slaunwhite E; Choudhari N; Kellet M; Storm PB; Resnick AC Proc Natl Acad Sci U S A; 2013 Apr; 110(15):5957-62. PubMed ID: 23533272 [TBL] [Abstract][Full Text] [Related]
10. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544 [TBL] [Abstract][Full Text] [Related]
11. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020 [TBL] [Abstract][Full Text] [Related]
12. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas. Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165 [TBL] [Abstract][Full Text] [Related]
13. Role of diffusion weighted imaging for differentiating cerebral pilocytic astrocytoma and ganglioglioma BRAF V600E-mutant from wild type. Ramaglia A; Tortora D; Mankad K; Lequin M; Severino M; D'Arco F; Löbel U; Benenati M; de Leng WWJ; De Marco P; Milanaccio C; Rossi A; Morana G Neuroradiology; 2020 Jan; 62(1):71-80. PubMed ID: 31667545 [TBL] [Abstract][Full Text] [Related]
14. BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma. Koelsche C; Sahm F; Paulus W; Mittelbronn M; Giangaspero F; Antonelli M; Meyer J; Lasitschka F; von Deimling A; Reuss D Neuropathol Appl Neurobiol; 2014 Apr; 40(3):337-44. PubMed ID: 23822828 [TBL] [Abstract][Full Text] [Related]
15. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002 [TBL] [Abstract][Full Text] [Related]
16. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238 [TBL] [Abstract][Full Text] [Related]
17. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
18. The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features. Cykowski MD; Allen RA; Kanaly AC; Fung KM; Marshall R; Perry A; Stolzenberg ED; Dunn ST J Neurooncol; 2013 Dec; 115(3):477-86. PubMed ID: 24057326 [TBL] [Abstract][Full Text] [Related]
19. Combined BRAF Zhang J; Yao TW; Hashizume R; Hariono S; Barkovich KJ; Fan QW; Prados M; James CD; Weiss WA; Nicolaides T J Neurooncol; 2017 Feb; 131(3):495-505. PubMed ID: 27848137 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations. Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]